ArticleGut and liver2026
Effects of Chemotherapy on Survival Outcomes in Older Patients with Metastatic Pancreatic Cancer: A Nationwide Population-Based Study.
Article in Gut and liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Clinical data on chemotherapy outcomes in older patients with pancreatic cancer are limited. This population-based study aimed to evaluate the effects of chemotherapy on survival outcomes in older patients with metastatic pancreatic cancer (mPC). Methods: Data from the National Health Insurance Service linked to the Korea Central Cancer Registry (2012 to 2019) were used. We assessed chemotherapy utilization and overall survival (OS) across various age groups and chemotherapy regimens. Results: Among 20,549 patients with mPC, 8,652 received chemotherapy, including 711 and 163 patients aged 76-80 and ≥81 years, respectively. In the chemotherapy group, the median OS (mOS) was 9, 8, 7, and 6 months for the 21-70, 71-75, 76-80, and ≥81-year age groups, respectively (p<0.001). In contrast, untreated patients had an mOS of only 2 months across all age groups. Propensity score matching for patients aged ≥76 years revealed that chemotherapy was associated with a significantly longer mOS compared with no treatment (7 months vs 2 months: hazard ratio, 0.3; 95% confidence interval, 0.271 to 0.333; p<0.001). Among patients treated with gemcitabine plus nab-paclitaxel, the mOS was 11, 10, 9, and 7 months across the age groups, respectively (p<0.001). For those receiving the FOLFIRINOX regimen, the mOS was 12, 11, and 10 months in patients aged 21-70, 71-75, and 76-80 years, respectively (p=0.001). Conclusions: These real-world data suggest that chemotherapy is effective in older patients with mPC. Notably, chemotherapy with gemcitabine plus nab-paclitaxel and FOLFIRINOX provided substantial survival benefits even in patients aged 76-80 years, with only marginal differences compared to younger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.